Budipine (BioDeep_00000176861)
human metabolite blood metabolite Volatile Flavor Compounds
代谢物信息卡片
化学式: C21H27N (293.21433820000004)
中文名称: 布地平
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(C)(C)N1CCC(CC1)(C1=CC=CC=C1)C1=CC=CC=C1
InChI: InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3
描述信息
D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents
N - Nervous system > N04 - Anti-parkinson drugs > N04B - Dopaminergic agents
C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent
C93038 - Cation Channel Blocker
Budipine is an anti-parkinson agent. Budipine also is a substrate of P-glycoprotein (P-gp), is mediated the uptake into the brain by P-gp. Budipine also is N-methyl-d-aspartate (NMDA) antagonist, and has indirect dopaminergic effects through an improved dopamine release, the inhibition of monoamine oxidase type B (MAO-B). Budipine can be used for the research of CNS disorders include Parkinson disease[1].
同义名列表
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:135228
- PubChem: 68778
- HMDB: HMDB0249425
- DrugBank: DB13502
- ChEMBL: CHEMBL334491
- Wikipedia: Budipine
- chemspider: 62021
- CAS: 57982-78-2
- medchemexpress: HY-W001601
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Manfred Uhr, Martin Ebinger, Marcus C Rosenhagen, Markus T Grauer. The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice.
Neuroscience letters.
2005 Jul; 383(1-2):73-6. doi:
10.1016/j.neulet.2005.04.020. [PMID: 15936515] - Amelie Lupp, Steffen Kerst, Elke Karge. Evaluation of possible pro- or antioxidative properties and of the interaction capacity with the microsomal cytochrome P450 system of different NMDA-receptor ligands and of taurine in vitro.
Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.
2003 Jun; 54(5-6):441-8. doi:
10.1078/0940-2993-00280. [PMID: 12877357] - T H Bethke, M Merz, K Zech, M Seiberling, D Hauschke, H Heinze, W Wurst. Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration.
International journal of clinical pharmacology and therapeutics.
2001 Jun; 39(6):259-64. doi:
10.5414/cpp39259. [PMID: 11430634] - S Lelas, S Wegert, S V Otton, E M Sellers, C P France. Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys.
Drug and alcohol dependence.
1999 May; 54(3):239-49. doi:
10.1016/s0376-8716(98)00169-0. [PMID: 10372797] - D M Tomkins, S V Otton, N Joharchi, T Berns, D Wu, W A Corrigall, E M Sellers. Effect of CYP2D1 inhibition on the behavioural effects of d-amphetamine.
Behavioural pharmacology.
1997 Jun; 8(2-3):223-35. doi:
NULL. [PMID: 9833017] - D M Tomkins, S V Otton, N Joharchi, N Y Li, R F Balster, R F Tyndale, E M Sellers. Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats.
The Journal of pharmacology and experimental therapeutics.
1997 Mar; 280(3):1374-82. doi:
NULL. [PMID: 9067326] - O Caputo, G Grosa, M Ceruti, F Rocco, G Biglino. The metabolic fate of the anti-parkinsonian drug budipine in rats.
European journal of drug metabolism and pharmacokinetics.
1991 Apr; 16(2):113-8. doi:
10.1007/bf03189947. [PMID: 1936070] - K Jellinger, H Bliesath. Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo.
Journal of neurology.
1987 Jun; 234(5):280-2. doi:
10.1007/bf00314280. [PMID: 3302121]